Biotech News

Arcutis Appoints Rob Scott, MD to Board of Directors

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsCommercial

WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of

Related news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

Stock data

Close
27.17 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States